^
Association details:
| Biomarker: | CDKN2A deletion |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos
Published date:
11/01/2018
Excerpt:
CDKN2A (5/7, 71%) was frequently deleted, and the deletion was only observed in the ibrutinib-resistant tumors (p = 0.010).
DOI:
https://doi.org/10.1182/blood-2018-99-117279
Trial ID:
